Acer Inc. was founded in 1976 by Stan Shih and is a Taiwan-based global technology company with operations in over 160 countries. Building on its strong foundation in computing and data technologies, Acer has strategically expanded into the biomedical field to develop a next-generation RNA therapeutics platform. Since 2018, the company has focused on personalized cancer vaccines, powered by proprietary AI models for high-precision neoantigen prediction. This AI-driven engine enables rapid identification of clinically relevant targets, significantly accelerating and improving the design of individualized immunotherapies. In 2021, Acer established its mRNA-LNP platform and has since developed a proprietary ionizable lipid, AIL-111, engineered for high delivery efficiency and favorable in vivo performance. This platform enables robust mRNA delivery and serves as the foundation for multiple therapeutic applications. Leveraging this core capability, Acer is advancing a targeted LNP (tLNP) platform for cell-specific delivery, including in vivo CAR-T cell generation, where mRNA is directly delivered to T cells within the body to induce transient CAR expression. This approach has the potential to simplify manufacturing, reduce cost, and improve accessibility compared to conventional ex vivo cell therapies. By integrating AI-driven antigen discovery, proprietary LNP delivery technology, and in vivo cell engineering, Acer is building a scalable and modular platform for next-generation RNA medicines. The company aims to become a key innovator at the intersection of digital technology and biopharmaceutical development, enabling transformative therapies for cancer and beyond.
AB DigiHealth Inc.
AB DigiHealth Inc. stands as a pioneering, modern core laboratory dedicated to advancing genomic research. Originating as a startup from Center for Genomic Medicine, National Cheng Kung University in Taiwan, our mission is to bridge the gap between scientific discoveries and clinical applications, providing a comprehensive solution for maternal-fetal precision medicine to the world. Harnessing state-of-the-art Next-Generation Sequencing (NGS) technology, advanced bioinformatics, and AI predictive algorithms, our goal is to usher prenatal genetic testing into a new era. As guardians of maternal-fetal health, we endeavor to create an efficient, empowering digital solution that leverages cloud-based NGS analytics pipelines and AI-based companion diagnosis. Our vision is to establish a next-generation healthcare system characterized by high accuracy, enhancing operational efficiency in laboratories and clinics.